Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
ElevateBio
United States
- Waltham, Massachusetts
- 25/05/2023
- Series D
- $401,000,000
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp is a purpose-built, technology-enabled manufacturing platform offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for viral vectors, RNA, and cell therapy production. Through BaseCamp, its expanding footprint, and its next-generation enabling technologies, ElevateBio is rapidly growing its collaborations with industry partners while also selectively developing its own portfolio of cellular and genetic medicines.
ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
- Industry Biotechnology Research
- Website https://elevate.bio/
- LinkedIn https://www.linkedin.com/company/elevatebio/
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)